In fiscal year 2025, CMG Pharmaceutical (058820) reported revenue of 105.2 billion KRW.
Income Statement
| Year | Revenue | Op Profit | Net Income | Source |
|---|
| 2025 | 105.2 billion KRW | -3.7 billion KRW | -10.1 billion KRW | [source] |
| 2024 | 99.1 billion KRW | 1.0 billion KRW | 2.7 billion KRW | [source] |
| 2023 | 93.9 billion KRW | 3.0 billion KRW | 6.5 billion KRW | [source] |
| 2022 | 82.2 billion KRW | 3.0 billion KRW | -388 million KRW | [source] |
| 2021 | 69.5 billion KRW | 1.7 billion KRW | 3.2 billion KRW | [source] |
Balance Sheet
| Year | Total Assets | Total Liabilities | Total Equity | Source |
|---|
| 2025 | 305.6 billion KRW | 103.3 billion KRW | 202.3 billion KRW | [source] |
| 2024 | 303.0 billion KRW | 112.8 billion KRW | 190.2 billion KRW | [source] |
| 2023 | 241.1 billion KRW | 50.7 billion KRW | 190.5 billion KRW | [source] |
| 2022 | 213.3 billion KRW | 28.3 billion KRW | 185.0 billion KRW | [source] |
| 2021 | 199.2 billion KRW | 14.5 billion KRW | 184.7 billion KRW | [source] |
Cash Flow
| Year | Operating | Investing | Financing | Source |
|---|
| 2025 | -11.0 billion KRW | 13.6 billion KRW | 946 million KRW | [source] |
| 2024 | 290 million KRW | -55.7 billion KRW | 56.8 billion KRW | [source] |
| 2023 | 3.9 billion KRW | -28.2 billion KRW | 21.1 billion KRW | [source] |
| 2022 | — | — | — | [source] |
| 2021 | — | — | — | [source] |
Cash flow figures for the relevant year were not collected.
